Wall Street Journal reports that Carl Icahn won a seat on Biogen Idec's board of directors, with the results of a possible second seat still up in the air, according to the article. "Icahn, who owns about 5.6% of Biogen and favors its break-up or sale, has claimed his candidates won two seats on Biogen's 13-member board, after a months-long proxy fight that ended Wednesday with a raucous shareholder meeting in Cambridge, Mass.," the article says. "After almost two years as an outsider and critic of Biogen, Mr. Icahn now has a toehold on its board and access to internal discussions at the company."
Premium Trial: